Business
Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients
Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), in a 45mg/0.5mL solution in a single-dose vial for subcutaneous injection. The additional presentation is approved for the treatment of pediatric patients aged 6 to 17 years, weighing less than 60kg, with plaque psoriasis (PsO) or psoriatic arthritis (PsA).[1] With this approval, STEQEYMA now offers all dosage fo
About this update from Celltrion, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Approval of 45mg/0.5mL solution in a single-dose vial for subcutaneous injection expands dosing flexibility for pediatric patients with plaque psoriasis (PsO) or psoriatic arthritis (PsA) under 60kg","length":198,"tagName":"p"}]},{"val":[{"type":"text","content":"The FDA previously approved STEQEYMA® 45mg/0.5mL, 90mg/mL in a single-dose prefilled syringe for subcutaneous injection, and 130mg/26mL in a single-dose vial for intravenous infusion in December 2024 ","length":199,"tagName":"p"}]},{"val":[{"type":"text","content":"STEQEYMA now matches all dosage forms and strengths of its reference product, STELARA®","length":86,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":483,"olType":false},{"type":"text","content":"INCHEON, South Korea, June 15, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), in a 45mg/0.5mL solution in a single-dose vial for subcutaneous injection. The additional presentation is approved for the treatment of pediatric patients aged 6 to 17 years, weighing less than 60kg, with plaque psoriasis (PsO) or psoriatic arthritis (PsA).[1] With this approval, STEQEYMA now offers all dosage forms and strengths of its reference product, providing flexibility to meet physicians' clinical needs while supporting treatment continuity for patients.","length":718,"tagName":"p"},{"type":"image","alt":"Celltrion CI (PRNewsfoto/Celltrion)","displaySize":"","headline":null,"caption":"Celltrion CI (PRNewsfoto/Celltrion)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/29f7024eb6887049478f3166bdb174c0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zhv97G9Xy8993_Mur..7KQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/29f7024eb6887049478f3166bdb174c0","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/2315627/Celltrion_CI_500px_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"In December 2024, the FDA approved STEQEYMA in 45mg/0.5mL and 90mg/mL solutions in a single-dose prefilled syringe for subcutaneous injection, and 130mg/26mL in a sing...